TNFSF10 and neoplasm: Three major features are considered to limit the therapeutic activity of conventional recombinant TRAIL proteins, low in vivo bioactivity and short plasma half-life (38), intrinsic or acquired resistance to TRAIL (39), and inefficient delivery of the proapoptotic protein to the tumor cells, altogether requiring multiple doses with potential increase in side effects (40).